🧬 HPV16-positive cervical squamous cell carcinoma
A malignant epithelial tumor of the cervix originating from the squamous epithelium, associated with infection by human papillomavirus type 16 (HPV16) — the most oncogenic strain among high-risk HPV types.
Pathophysiology:
HPV16 encodes E6 and E7 oncoproteins, which inactivate tumor suppressor genes p53 and RB1, respectively, leading to genomic instability and malignant transformation of cervical epithelial cells.
Clinical significance:
HPV16 is detected in approximately 50–60% of cervical squamous cell carcinomas worldwide.
Tumors positive for HPV16 may present distinct molecular profiles, radiation sensitivity, and potentially prognostic implications compared to HPV-negative cases.
Though usually locally invasive, rare hematogenous dissemination (e.g., to brain or cerebellum) has been documented in isolated reports.
Diagnosis:
Confirmed by histopathology of cervical biopsy.
HPV genotyping (PCR or in situ hybridization) identifies high-risk subtypes like HPV16.
Treatment:
Based on FIGO stage, standard treatment includes radiotherapy ± cisplatin-based chemotherapy, with brachytherapy for local control.